Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study.

Maria Rita Lo MonacoMartina PetraccaDavide Liborio VetranoEnrico Di StasioDomenico FuscoDiego RicciardiAlice LaudisioGiuseppe ZuccalàGraziano OnderAnna Rita Bentivoglio

Published in: Aging clinical and experimental research (2020)

Safinamide as an adjunct therapy in patients aged ≥ 60 years with advanced PD was found to be safe and well-tolerated in older patients. There were no specific demographic or clinical characteristics associated with suspension.

Keyphrases

physical activity
community dwelling
middle aged
stem cells
replacement therapy